Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

35.89 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Moderna and OpenAI Collaborate To Advance mRNA Medicine
Via ACCESSWIRE
News headline image
Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign
Via ACCESSWIRE
News headline image
Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
Via ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
Via ACCESSWIRE
News headline image
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
Via ACCESSWIRE
News headline image
Moderna to Present at Upcoming Investor Conferences in March 2024
Via ACCESSWIRE
News headline image
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
Via ACCESSWIRE
News headline image
Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
News headline image
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Via ACCESSWIRE
News headline image
Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
Via ACCESSWIRE
News headline image
Novavax’s dispute resolution and upcoming earnings call
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer. 
Via MarketBeat
Topics Earnings
News headline image
Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
Via ACCESSWIRE
News headline image
Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Via ACCESSWIRE
Moderna Inc. (NASDAQ: MRNA) Highlighted for Surprising Price Action
Via Investor Brand Network
News headline image
Moderna to Present at Upcoming Conferences in November 2023
Via ACCESSWIRE
News headline image
Moderna Named to Fortune's List of World's Most Admired Companies
Via ACCESSWIRE
News headline image
3 health care stocks off to strong starts in 2024
With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Are defensive sectors ready to outshine growth in 2024?
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead. 
Via MarketBeat
News headline image
MarketBeat Week in Review – 1/1 - 1/5
Stocks finished the week looking for direction after a hotter-than-expected Jobs report and as investors wait for inflation information and big bank earnings 
Via MarketBeat
Topics Economy
News headline image
3 reasons 2024 Moderna shareholders may party like it's 2021
With interest in Moderna Inc. stock picking up alongside news flow, investors could be in for some very healthy 2024 gains. 
Via MarketBeat
News headline image
Pfizer's chaotic year wraps up with plunging stock, grim guidance
Pfizer's tumultuous 2023 included a 41.84% stock plunge as revenue from Covid drugs fell. Disappointing 2024 guidance resulted in analysts slashing targets. 
Via MarketBeat
News headline image
Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
News headline image
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
Via ACCESSWIRE
News headline image
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following
Via ACCESSWIRE
News headline image
Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
Via ACCESSWIRE
News headline image
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
Via ACCESSWIRE
News headline image
Upwork underscores the strength of the AI gig economy
Upwork has been pursuing its goal of being the world's preeminent destination for artificial intelligence (AI) related talent and freelancers 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.